Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
Status:
RECRUITING
Trial end date:
2028-07-06
Target enrollment:
Participant gender:
Summary
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis